BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer
In HGOC BRCA mutational status together with BRCA1-methylation exhibit the best predictive power for favorable clinical outcome and thus high sensitivity to platinum-based therapy, whereas BRCA-unrelated HRD positivity was not associated with improved platinum sensitivity.
Authors
- Katharina Wimmer (ORCID: https://orcid.org/0000-0002-0732-7538)
- Simon Schnaiter (ORCID: https://orcid.org/0009-0009-5213-6237)
- Katharina Leitner (ORCID: https://orcid.org/0000-0002-9572-9114)
- Heidi Fiegl (ORCID: https://orcid.org/0000-0002-1236-6806)
- Christian Marth (ORCID: https://orcid.org/0000-0002-8965-9981)
- Irina Tsibulak (ORCID: https://orcid.org/0000-0001-6795-3015)
- Daniel Reimer (ORCID: https://orcid.org/0000-0003-1853-9365)
- Verena Wieser (ORCID: https://orcid.org/0000-0001-6121-2515)
- Esther Schamschula (ORCID: https://orcid.org/0000-0002-8874-1713)
- Alain G. Zeimet (ORCID: https://orcid.org/0000-0001-5306-2334)
- Petra Nardelli
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1186/s13148-024-01781-0
- Citations
- 8
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.26